Justin Moyers, MD
Medical Oncology · Orange, CANPI 1073925343
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,160 of the $3,298 with a category attached, or 65.5%. Array Biopharma Inc accounts for 69.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $2,669 and has fallen 96.5% since, to $93 in 2025. That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.
Across 14 payments — averaging $235.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Array Biopharma Inc$2K
- Coherus Oncology, Inc.$343
- E.r. Squibb & Sons, L.L.C.$152
- Amgen$121
- Takeda Pharmaceuticals U.S.A., Inc.$99
- Seagen Inc.$99
- plus $183 from 3 others
Across 263 payments — averaging $5220.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$1.2M
- Modernatx, Inc.$69K
- E.r. Squibb & Sons, L.L.C.$49K
- Merck$21K
What the payments were for
- Speaking & faculty fees$2,16065%
- Food & beverage$87226%
- Education$2668%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Array Biopharma Inc | 2 | $2,300 |
| Coherus Oncology, Inc. | 3 | $343 |
| E.r. Squibb & Sons, L.L.C. | 2 | $152 |
| Amgen | 2 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $99 |
| Seagen Inc. | 1 | $99 |
| Caris MPI, Inc. | 1 | $93 |
| Astellas Pharma US Inc | 1 | $65 |
| AbbVie | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,298 in reported general payments places this provider in the 45th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 15 | $159 |
| Warfarin Sodium | 12 | $21 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Orange
- Farshid DayyaniOrange$1.2M
- Susan O BrienOrange$414K
- Jennifer ValerinOrange$188K
- Sayeh LavasaniOrange$162K
- Victoria VillaflorOrange$91K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.